451 related articles for article (PubMed ID: 16904670)
1. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S; Moschetta A
FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
[TBL] [Abstract][Full Text] [Related]
2. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
Claudel T; Staels B; Kuipers F
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
[TBL] [Abstract][Full Text] [Related]
3. FXR: a metabolic regulator and cell protector.
Wang YD; Chen WD; Moore DD; Huang W
Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
[TBL] [Abstract][Full Text] [Related]
4. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
5. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
6. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
Mencarelli A; Renga B; Migliorati M; Cipriani S; Distrutti E; Santucci L; Fiorucci S
J Immunol; 2009 Nov; 183(10):6657-66. PubMed ID: 19880446
[TBL] [Abstract][Full Text] [Related]
7. FXR, a multipurpose nuclear receptor.
Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
[TBL] [Abstract][Full Text] [Related]
8. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Kuipers F; Stroeve JH; Caron S; Staels B
Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
[TBL] [Abstract][Full Text] [Related]
9. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
10. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
12. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
[TBL] [Abstract][Full Text] [Related]
13. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
[TBL] [Abstract][Full Text] [Related]
15. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
Duran-Sandoval D; Cariou B; Fruchart JC; Staels B
Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor agonists in biliary tract disease.
Fiorucci S; Baldelli F
Curr Opin Gastroenterol; 2009 May; 25(3):252-9. PubMed ID: 19300246
[TBL] [Abstract][Full Text] [Related]
17. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
18. A role of the bile salt receptor FXR in atherosclerosis.
Hageman J; Herrema H; Groen AK; Kuipers F
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
20. Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.
Nolan JD; Johnston IM; Walters JR
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):49-56. PubMed ID: 23265149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
